Get the Stockscreener App
5.135
1.93%
0.105
Mannkind Corp stock is traded at $5.135, with a volume of 238.02K.
It is up +1.93% in the last 24 hours and down -3.44% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
See More
Previous Close:
$5.03
Open:
$5.16
24h Volume:
238.02K
Relative Volume:
0.05
Market Cap:
$1.58B
Revenue:
$248.37M
Net Income/Loss:
$11.74M
P/E Ratio:
102.70
EPS:
0.05
Net Cash Flow:
$18.24M
1W Performance:
+2.96%
1M Performance:
-3.44%
6M Performance:
+24.45%
1Y Performance:
-25.04%
1-Day Range:
$5.07
$5.19
1-Week Range:
$4.93
$5.19
52-Week Range:
$3.3812
$7.07
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
5.135 | 1.54B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
431.35 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.53 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
444.62 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
905.13 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
203.94 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Oct-10-25 | Initiated | Leerink Partners | Outperform |
| Jul-16-25 | Resumed | H.C. Wainwright | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-10-25 | Initiated | Wedbush | Outperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-10-23 | Initiated | Wedbush | Outperform |
| May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-24-19 | Initiated | Oppenheimer | Outperform |
| Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-14-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
| Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
| Oct-10-17 | Initiated | H.C. Wainwright | Buy |
| Oct-06-17 | Reiterated | Maxim Group | Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| May-10-16 | Reiterated | Piper Jaffray | Underweight |
| May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
| Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
| Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
| Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
| Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
| May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| May-11-15 | Reiterated | MLV & Co | Hold |
| Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
MannKind stock initiated with Buy rating at Truist on Tyvaso DPI potential - Investing.com
MannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Will MannKind Corporation stock outperform value stocksMarket Activity Recap & Accurate Intraday Trading Signals - newser.com
Is MannKind Corporation (NNFN) stock a contrarian opportunityPortfolio Risk Report & Intraday High Probability Alerts - newser.com
Why MannKind Corporation (NNFN) stock attracts wealthy investorsTrend Reversal & Safe Entry Momentum Tips - newser.com
What momentum indicators show for MannKind Corporation stock2025 Earnings Impact & Step-by-Step Trade Execution Guides - newser.com
How MannKind Corporation stock performs after earningsJuly 2025 PreEarnings & Weekly High Momentum Picks - newser.com
How MannKind Corporation (NNFN) stock trades under stagflationMarket Activity Report & Free Technical Confirmation Trade Alerts - newser.com
Is MannKind Corporation (NNFN) stock attractive post correction2025 Fundamental Recap & Verified Short-Term Plans - newser.com
MannKind at Jefferies London Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Nigeria
Is MannKind Corporation stock cheap compared to fundamentalsShare Buyback & Safe Swing Trade Setups - newser.com
MannKind at Jefferies London Healthcare Conference: Strategic Growth Insights - Investing.com India
Can MannKind Corporation (NNFN) stock sustain double digit ROE2025 Price Momentum & Fast Exit Strategy with Risk Control - newser.com
Is MannKind Corporation (NNFN) stock a safe buy pre earnings2025 Top Decliners & AI Driven Stock Reports - newser.com
Technical signs of recovery in MannKind CorporationTrade Ideas & Stepwise Trade Signal Implementation - newser.com
Mitsubishi UFJ Asset Management Co. Ltd. Buys Shares of 67,889 MannKind Corporation $MNKD - MarketBeat
Will MannKind Corporation stock maintain dividend yieldQuarterly Performance Summary & Daily Market Momentum Tracking - newser.com
Insider Selling: MannKind (NASDAQ:MNKD) EVP Sells $94,448.31 in Stock - MarketBeat
Can swing trading help recover from MannKind Corporation losses - newser.com
Connor Clark & Lunn Investment Management Ltd. Decreases Position in MannKind Corporation $MNKD - MarketBeat
Insider Sell: Sanjay Singh Sells Shares of MannKind Corp (MNKD) - GuruFocus
Will MannKind Corporation continue its uptrend2025 Historical Comparison & Reliable Intraday Trade Plans - newser.com
Mannkind EVP Singh sells $94k in stock By Investing.com - Investing.com Canada
Mannkind EVP Singh sells $94k in stock - Investing.com
MannKind (NASDAQ:MNKD) Now Covered by Leerink Partners - MarketBeat
MannKind (NASDAQ:MNKD) Price Target Lowered to $8.00 at Wells Fargo & Company - MarketBeat
Visual analytics tools that track MannKind Corporation performanceMarket Movement Recap & Consistent Profit Trade Alerts - newser.com
Can MannKind Corporation (NNFN) stock attract analyst upgradesJuly 2025 Analyst Calls & Free Long-Term Investment Growth Plans - newser.com
MannKind (Nasdaq: MNKD) to present at Jefferies; webcast Nov. 19 at 6:30 am ET - Stock Titan
RBC Capital Maintains MannKind (MNKD) Outperform Recommendation - Nasdaq
MannKind (NASDAQ:MNKD) Shares Gap DownHere's What Happened - MarketBeat
RBC Capital Adjusts MNKD Price Target, Maintains Outperform Rati - GuruFocus
Wells Fargo Lowers Price Target for MannKind (MNKD) Amid Overwei - GuruFocus
MannKind stock price target lowered to $7.50 at RBC on NTM trial failure - Investing.com
MannKind stock falls after discontinuing Phase 3 NTM lung disease trial - Investing.com Canada
Danbury biopharma firm halts late-stage drug trial after disappointing results - Hartford Business Journal
MannKind Corp. Hits Day High with Strong 10.58% Intraday Surge - Markets Mojo
MannKind (MNKD) Halts Phase 3 Trial Due to Ineffectiveness - GuruFocus
MannKind (MNKD) Halts MNKD-101 Trial, Stock Falls 10% - GuruFocus
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.28%
2.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):